Dr. Pooja Manroa, MD

Dr. Manroa practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Manroa's NPI, 1831487552, was assigned on July 15, 2011. Dr. Manroa graduated from Topiwala National Medical College in 2009. Dr. Manroa holds California license C177826.

Dr. Manroa's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Manroa's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Manroa to 2 more medical groups, 1 group practice or clinic and 1 other site, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Manroa practices, 2 sites in all. Vendor and product names are available with a free account.

Endocrinology, diabetes and metabolism is Dr. Manroa's primary specialty in the NPI Registry, under taxonomy code 207RE0101X. Dr. Manroa is board certified in endocrinology and metabolism by the American Board of Internal Medicine. Dmand AI has Dr. Manroa's licenses on file in 4 states: California, Texas, Pennsylvania and Ohio.

Dmand AI lists chronic diabetes, diabetic emergency, enlarged thyroid, fluid and electrolyte imbalances, hypercalcemia, obesity, osteoporosis and parathyroid gland disorder among the conditions Dr. Manroa treats.

CMS data shows 667 Medicare services from Dr. Manroa across 7 procedure codes in 2024, for 320 Medicare patients. Medicare paid $52,768 for them.

CMS counts 320 Medicare patients who saw Dr. Manroa in 2024. The largest group is 65 to 74, with 156 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 41% are also on Medicaid. Their average risk score is 2.79, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Manroa's median patient age at 64, with 67% women.

In 2024, Dr. Manroa wrote 843 Medicare Part D claims for 183 patients. 47% of them were for generic drugs. CMS names the drug for 571 of them, across 20 drugs with 11 or more claims each, at $240,901 in total drug cost. In 2023, CMS named 561 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Manroa for performance year 2024, reported as part of a group. Dr. Manroa accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Manroa as offering telehealth.

Dmand AI links 12 papers to Dr. Manroa, published from 2014 to 2021. 2014 was the busiest year, with 3. The most frequent topics are Biopsy, Fine-Needle, Thyroid Neoplasms and Thyroid Nodule. Dr. Manroa has published most often in Endocr Pract. Dr. Manroa's most frequent co-authors are Elena M. Morariu, Linwah Yip, MD and Runa Acharya, MD.

CMS Open Payments shows 51 general payments to Dr. Manroa from 18 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Amgen Inc. paid the most, $286.

Dr. Manroa graduated from Topiwala National Medical College in 2009. Dr. Manroa is a member of AACE, ADA and Endocrine Society.

Dr. Manroa is in network with 21 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.